Does retatrutide deplete vitamin B1?

The direct-depletion claim is not in the literature

No verified publication reports that retatrutide consumes, binds, degrades or otherwise chemically depletes thiamine. The retatrutide trial programme — phase 2 in obesity and type 2 diabetes, and the TRANSCEND-T2D-1 phase 3 trial — measured efficacy and adverse events, not micronutrient biomarkers. Any site claiming established direct depletion is ahead of the evidence.

The indirect pathway is documented at every step

Step one — intake falls, and stays down. A 60-week, double-blind randomized controlled trial of semaglutide 2.4 mg measured roughly 240–290 kcal/day lower ad libitum energy intake versus placebo for the full treatment duration: the reduced-intake window is not a transient titration effect but a sustained exposure.

Step two — gastrointestinal symptoms are common. In the retatrutide phase 2 type-2- diabetes trial, nausea, vomiting and diarrhoea occurred in up to around half of participants at higher doses; in TRANSCEND-T2D-1, gastrointestinal events were the most frequent adverse events.

Step three — vomiting plus rapid weight loss is the historical recipe for thiamine deficiency. In Aasheim’s landmark review of 84 Wernicke encephalopathy cases after bariatric surgery, 90% were preceded by frequent vomiting (median 21 days), 94% presented within six months, and 49% recovered incompletely. Oudman’s synthesis of 586 non-alcoholic Wernicke-Korsakoff cases confirms vomiting and extreme weight loss as strong predictors.

Step four — the outcome is now appearing in the incretin literature. A PRISMA systematic review identified six Wernicke encephalopathy cases after semaglutide for obesity, all preceded by prolonged gastrointestinal symptoms and substantial weight loss, with outcomes including Korsakoff progression and death. FAERS and WHO VigiBase disproportionality analyses add class-level signals (ROR 2.35 in FAERS; 19 cases in VigiBase, 68% with nausea, vomiting or reduced intake).

Direct depletion or reduced intake? How to tell them apart

The distinction is testable, not rhetorical. Direct depletion would predict thiamine status falling out of proportion to intake loss; the indirect mechanism predicts status tracking intake, dietary quality and gastrointestinal symptom burden. Whole-blood thiamine pyrophosphate by LC-MS/MS — with published healthy-adult reference intervals of 101–189 nmol/L — and erythrocyte transketolase activity are the measurement tools. No study has yet applied them prospectively to retatrutide-treated individuals; that measurement gap is one reason the Reta-B1 programme exists.

The Panacea position

Potent appetite suppression, reduced dietary intake, gastrointestinal intolerance and rapid weight reduction may create nutritional vulnerability in some individuals. Panacea Bio Chem is investigating whether integrating thiamine into a once-weekly retatrutide formulation could provide a more coherent pharmaceutical research architecture. Reta-B1 does not assume that retatrutide directly consumes or chemically depletes thiamine — that mechanism has not been established.